Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the initiation of patient recruitment for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to potentially eliminate the need for corrective lenses. The clinical facility in Mexico City, which successfully performed Group One surgeries in Fall 2025, has begun identifying and recruiting eligible patients for surgeries targeted for Fall 2026.
This announcement marks a significant progression from the Group One study, which focused solely on safety. Group Two will evaluate the lens for safety plus near- and distance-vision performance, according to the company's press release. Patients in this group will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system, reflecting the company's continued technological evolution.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about advancing to the next phase: "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
The company also highlighted that Group One patients are reaching their 12-month follow-ups, providing longer-term clinical data. Burns noted, "We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens." He added that the Group Two study introduces the next-generation lens and delivery system, representing "the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
According to the company, the Group One clinical outcomes "met and exceeded" expectations regarding safety, performance, and handling of the lens. Patients have continued to be monitored as part of the ongoing clinical evaluation.
The Ocumetics Lens is a dynamic intraocular lens that fits within the natural lens compartment of the eye. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially providing clear vision at all distances without glasses or contact lenses. This technology could have profound implications for the ophthalmic industry and for millions of people worldwide who rely on corrective lenses.
If successful, this lens could transform vision correction, offering an alternative to laser surgery and traditional intraocular lenses used in cataract procedures. The ability to restore accommodation—the eye's ability to change focus—has been a long-sought goal in ophthalmology. Current intraocular lenses used in cataract surgery typically provide fixed focus, often requiring patients to use glasses for near or intermediate vision. The Ocumetics Lens aims to overcome this limitation, potentially improving quality of life for patients.
For business leaders in the medical device and healthcare sectors, this development signals continued innovation in vision technology. The successful progression of clinical trials could lead to a disruptive product in the intraocular lens market, which is projected to grow significantly due to an aging population and increasing prevalence of cataracts. Moreover, the company's focus on next-generation delivery systems may enhance surgical outcomes and adoption rates among ophthalmologists.
Ocumetics is conducting this first-in-human early feasibility study, and the results will be critical in determining the viability of the technology. The company's progress will be closely watched by investors and industry stakeholders, as positive outcomes could position it as a leader in accommodating intraocular lenses.
As the company moves forward with Group Two surgeries and awaits 12-month data from Group One, the ophthalmic community anticipates the potential impact of this technology. If the Ocumetics Lens proves safe and effective, it could redefine vision correction and set a new standard for intraocular lens performance.
For more information, visit NewMediaWire.
